title: [Fisher syndrome and Bickerstaff brainstem encephalitis].
abstract: This review described current status and perspectives of treatment for immune-mediated neuropathies, such as Guillain-Barre syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), multifocal motor neuropathy, and demyelinating neuropathy with anti-MAG neuropathy. corticosteroids, immunoglobulin therapy, and plasmapheresis are conventional treatments for these neuropathies, but the responsiveness to the treatments significantly differ among the disorders. Promising new treatment options include anti-complement monoclonal antibody (Eculizumab, anti-C5) for Guillain-Barre syndrome, and rituximab (anti-CD20) for anti-MAG neuropathy. For CIDP, different treatments would be required according to the clinical subtypes; typical CIDP and asymmetric variabt). For multifocal neuropathy, maintainance treatment with immunoglobulin is necessary.
authors: Department of Neurology, Graduate School of Medicine, Chiba University.
authors: Satoshi
authors: S
authors: Kuwabara
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D004660:Encephalitis / Q000276:immunology / Q000628:therapy; D006801:Humans; D007136:Immunoglobulins / Q000627:therapeutic use; D019846:Miller Fisher Syndrome / Q000276:immunology / Q000628:therapy; D010956:Plasmapheresis; D020277:Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / Q000276:immunology / Q000628:therapy; D000069283:Rituximab
chemical_list: D000305:Adrenal Cortex Hormones; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D007136:Immunoglobulins; D000069283:Rituximab; C481642:eculizumab